1403.2: Phase 1 dose-escalation study of brigimadlin (MDM2-p53 antagonist) with ezabenlimab (PD-1 inhibitor) in patients with advanced solid tumors
NCT03964233. https://clinicaltrials.gov/ct2/show/NCT03964233. Accessed September 2023.
NCT03964233. https://clinicaltrials.gov/ct2/show/NCT03964233. Accessed September 2023.